Copyright © Inderes 2011 - present. All rights reserved.

Bioretec

0.70 EUR

-1.41 %

1,699 following

BRETEC

First North Finland

Medical Equipment & Services

Health Care

-1.41 %
-26.32 %
-49.09 %
-59.77 %
-69.55 %
-67.81 %
-53.45 %
-
-75.15 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
21.55M EUR
Turnover
63.64K EUR
P/E (adj.) (25e)
-2.3
EV/EBIT (adj.) (25e)
-2.06
P/B (25e)
2.29
EV/S (25e)
4.52
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
1.05 EUR
Updated
14.11.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 14.11.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Here is a new company report on Bioretec from Antti. Bioretec’s Q3 business review shed light on the company’s situation and the commercial challenges of the RemeOs product family. Growth for the new product family is expected to be delayed until 2026. The company is seeking new ...
11/14/2025, 5:52 AM
by Sijoittaja-alokas
6
And here’s a link to the interview where Antti interviewed CEO Sarah Hubar-Fisher regarding Q3. Inderes Bioretec Q3'25: Necessary revisions ahead - Inderes Aika: 13.11.2025 klo 11.55 In connection with its Q3 business review, Bioretec shed light on its situation and the commercial...
11/13/2025, 11:00 AM
by Sijoittaja-alokas
6
Numbers were obtained, but no mentions of European departure. So we can assume that there is hardly any sales here yet. Likewise, for USA remeosis, Q3 was again utterly dismal. Cash is burning at a nice pace and we can expect zero profit. It would be interesting to see the breakdown...
11/13/2025, 7:09 AM
by Umpi
6
Q3 revenue only 30 thousand more than last year (approx. +4.4%). Antti’s expectation was +47.2%. EBITDA and operating loss almost in line with Antti’s forecasts. Tärkeimmät talousuutiset | Kauppalehti – 13 Nov 25 Bioretec Oy:n liiketoimintakatsaus tammi-syyskuu 2025: Vahvistamme....
11/13/2025, 6:47 AM
by Roni
4
Is it reasonable to speculate whether some entity more skilled in marketing would buy this? The product, to my understanding, is functional, but with current efforts, it’s not generating enough revenue. With the current results, it would now be driven perhaps even deeper into the...
11/12/2025, 4:51 PM
by Cezeta
4
Antti has already provided quick comments on the Q3 business review. On Thursday morning, Bioretec published its Q3 business review, which shed light on the company’s situation and the commercial challenges of the RemeOs product family. The company is seeking new commercial momentum...
11/13/2025, 8:02 AM
by Sijoittaja-alokas
3
Bioretec has a “breakthrough” product that the FDA and the corresponding EU agency have approved. I asked Bioretec how it’s possible that the product cannot be sold even though it is superior compared to “previous” practices. They have not responded.
11/12/2025, 6:17 PM
by KAMELI
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.